NCT00462150

Brief Summary

The purpose of the study is threefold: 1) to develop a home-based emotional disclosure intervention inducing core elements of change (emotional engagement, cognitive restructuring, and positive future directedness); 2) to examine in a randomized controlled trial in patients with rheumatoid arthritis the induction of the core elements and the feasibility of the intervention for home application; and, 3) to examine the psychological, clinical, and physiological effects of the adapted emotional disclosure intervention and the modulating role of cognitive-emotional change and individual differences in emotion regulation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P25-P50 for phase_2 rheumatoid-arthritis

Timeline
Completed

Started Sep 2002

Shorter than P25 for phase_2 rheumatoid-arthritis

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2002

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2003

Completed
3.9 years until next milestone

First Submitted

Initial submission to the registry

April 16, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 18, 2007

Completed
Last Updated

April 18, 2007

Status Verified

April 1, 2007

First QC Date

April 16, 2007

Last Update Submit

April 16, 2007

Conditions

Keywords

arthritis, rheumatoidexpressed emotionrandomized controlled trialaffectblood sedimentationpsychophysiologyfeasibility studiesintervention studiestime management

Outcome Measures

Primary Outcomes (3)

  • Depressed mood.

  • Cheerful mood.

  • Both measures at baseline, 1 week after intervention, and 3 months after intervention.

Secondary Outcomes (4)

  • Feasibility: adherence, compliance with instructions, perceived viability, clinical safety; all measured during or immediately after the intervention).

  • Induction of core elements: immediate negative affect change, emotion, insight, and optimism word use during the intervention.

  • Clinical measures: Joint score; Erythrocyte Sedimentation Rate; both measures at baseline, 1 week after intervention, and 3 months after intervention.

  • Physiological measures: 24-h Urinary cortisol; 24-h Urinary noradrenaline; IL-6; IFN-γ; IL-10; all measures at baseline, 1 week after intervention, and 3 months after intervention.

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of rheumatoid arthritis according to the criteria of the American College of Rheumatology (Arthritis Rheum 1988;31:315-24
  • Written informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Utrecht University, Department of Clinical and Health Psychology

Utrecht, Utrecht, PO Box 80.140, 3508 TC, Netherlands

Location

Related Publications (1)

  • van Middendorp H, Sorbi MJ, van Doornen LJ, Bijlsma JW, Geenen R. Feasibility and induced cognitive-emotional change of an emotional disclosure intervention adapted for home application. Patient Educ Couns. 2007 May;66(2):177-87. doi: 10.1016/j.pec.2006.11.009. Epub 2007 Mar 1.

MeSH Terms

Conditions

Arthritis, Rheumatoid

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Henriët van Middendorp, PhD

    Utrecht University, Department of Clinical and Health Psychology

    PRINCIPAL INVESTIGATOR
  • Rinie Geenen, PhD

    Utrecht University, Department of Clinical and Health Psychology

    STUDY CHAIR
  • Johannes WJ Bijlsma, PhD, MD

    University Medical Center Utrecht, Department of Rheumatology & Clinical Immunology

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 16, 2007

First Posted

April 18, 2007

Study Start

September 1, 2002

Study Completion

June 1, 2003

Last Updated

April 18, 2007

Record last verified: 2007-04

Locations